Select region:

Clinical trials located in


Edinburgh city is located in United Kingdom. Currently, 20 clinical trials are being conducted in this city.

Edinburgh, the capital city of Scotland, is steeped in history and culture. Dominated by the iconic Edinburgh Castle, the city is famous for its well-preserved medieval and Georgian architecture. Edinburgh is also known for hosting the world’s largest arts festival, the Edinburgh Festival Fringe. The city’s Old and New Towns are UNESCO World Heritage Sites, showcasing a blend of historical and modern life. Birthplace of renowned figures like Sir Arthur Conan Doyle and the setting for the world-famous Harry Potter series, Edinburgh offers a rich tapestry of literary and cultural heritage.

  • CT-EU-00034272

    Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    BelgiumCzechiaFranceGreeceHungaryNetherlandsPolandSpainUnited Kingdom
  • Fianlimab and cemiplimab: a new treatment for melanoma patients

    The study is underway to determine the most effective treatments in preventing the recurrence of melanoma, a form of skin cancer, following surgical removal. The medicines being tested are Fianlimab and Cemiplimab together or another medicine called Pembrolizumab. The trial aims to assess whether the Fianlimab and Cemiplimab combination outperforms Pembrolizumab in preventing cancer recurrence and if patients administered Fianlimab and Cemiplimab live longer. Additionally, the study seeks insights into the impact of treatments on patients’ quality of life, the occurrence of minor or major side effects, and how these drugs behave inside the patient’s body.

    BelgiumCzechiaFranceGermanyGreeceItalyPolandRomaniaSpainUnited Kingdom
  • Evaluating dostarlimab for treating stage III colon cancer

    This research is focused on the investigation of the effect of dostarlimab on patients with severe, untreated colon cancer (T4N0 or Stage III dMMR/MSI-H). The primary objective is to assess whether dostarlimab yields superior outcomes for the patients in comparison to standard treatments. Patient monitoring will be based on tumor response and the potential impact on their quality of life resulting from the drug or disease progression.

    BelgiumFinlandFranceGermanyGreeceItalyNetherlandsNorwayPortugalSpainSwedenUnited Kingdom
  • Use of tucatinib in combination therapy for HER2-positive breast cancer

    This study examines whether tucatinib, combined with other medications, is more effective than a placebo in treating HER2-positive breast cancer. The research will also identify any side effects from the drug combination. Participants in this study have advanced breast cancer that is either unresectable (cannot be surgically removed) or metastatic (spread throughout the body). Participants will be randomly assigned to receive either tucatinib or a placebo, without knowing which one they are receiving. This method ensures the study’s fairness and accuracy. Additionally, all participants will receive trastuzumab and pertuzumab, two drugs effective against this cancer type. These will be administered every 21 days, either intravenously or subcutaneously, depending on the specific drug and combination used. The study has two main groups: one receiving a placebo and the other tucatinib, both alongside trastuzumab and pertuzumab.

    AustriaBelgiumCzechiaFinlandFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Testing new combination treatments for kidney cancer

    This study, part of a broader research project exploring new treatments for kidney cancer, specifically Renal Cell Carcinoma (RCC). These treatments include different combinations of drugs from among the listed: Pembrolizumab, Favezelimab, Belzutifan, Lenvatinib, Quavonlimab and Vibostolimab. The research comprises two stages: a safety assessment stage and an efficacy evaluation stage. In the first stage, the study aims to determine the safety and tolerability of a few different drug combinations. The study will monitor any unexpected adverse health events and track the number of participants who may need to discontinue the treatment due to health concerns. In the second stage, the study will assess the effectiveness of these various drug combinations and identify any uncomfortable or unwelcome effects. Additionally, researchers will observe how many participants can continue the treatment without experiencing adverse effects.

    FranceHungaryNetherlandsPolandSpainUnited Kingdom
  • Comparing Imlifidase with standard treatment in anti-glomerular basement membrane disease

    This clinical trial is testing a medication called Imlifidase in patients who have a serious disease called anti-GBM (Goodpasture syndrome). The researchers are doing this study to compare two groups: people who take Imlifidase along with the usual treatment, and people who only get the usual treatment. This typical treatment consists of plasma exchange (PLEX), Cyclophosphamide and glucocorticoids. This study will last for 2 years. Researchers will measure things like kidney function, levels of harmful anti-GBM antibodies, breathing symptoms, drug interaction and patients’ quality of life.

    CzechiaDenmarkFranceGermanyItalyNetherlandsSpainSwedenUnited Kingdom
  • Research on using new therapy for treating advanced tumors

    This research is about a new medicine named INCB123667. It may help people who have serious cancers that have spread to other parts of the body. The trial has two parts. Part 1 will find out the best dose to use and if it causes any side effects. Part 2 will see if the medicine helps shrink the cancer cells. Doctors will check for side effects the first time the medicine is given. If side effects are severe, the medicine dose will be reduced. The timing of when the drug is given may also need to be changed. Doctors will measure the highest amount of the drug in the blood and how fast it reaches this level. They’ll also see how long it stays in the system and how quickly the body gets rid of it. Successful treatment would mean the cancer stops growing or shrinks.

    FranceItalyNetherlandsUnited Kingdom
  • Study on a new medicine for Aicardi-Goutières syndrome

    This research study revolves around a drug called TPN-101, being tested for people with a disease called Aicardi-Goutires Syndrome or AGS. The researchers want to involve a few people between 10-16, who are over a year old and weigh over 10 kg. They’ll get the mentioned drug, the dose of which they’ll adjust depending on their weight, anywhere from 100 mg to 400 mg, so everyone gets an equal percentage. There are three parts to the study. First, they’ll check everyone’s health for 6–8 weeks before starting. Then, for the next 48 weeks, patients will regularly take TPN-101. Then, over 12 weeks, the researchers will see how everyone’s doing, without the medication. They’ll be looking for any side effects and response to the treatment during the study.

    FranceItalyUnited Kingdom
  • Testing navitoclax and ruxolitinib effective on myelofibrosis patients

    This study is trying to find out if the combination of two drugs called Navitoclax and Ruxolitinib can help people with a type of blood cancer called Myelofibrosis. Around 330 adults, who have myelofibrosis that hasn’t responded to previous treatments, will get either the new drug combination or the current best treatment for their disease. Doctors will measure whether the new combination is more effective by checking how much the size of participants’ spleens have changed during the study with scans, measuring fatigue levels and checking how well their bone marrow works.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyPolandSpainSwedenUnited Kingdom
  • Study on new drug’s effect on growing desmoid tumors

    This research is about the effect of a medication named AL102 on Desmoid tumors that continue to grow worse. The study is in 2 phases. In phase 1, every patient will receive AL102, and researchers will determine the ideal dosage of the drug. In phase 2, some of those patients will receive AL102 while others will get a substance without any medicine in it (a placebo). The study aims to provide new insights and potentially a new treatment option for this condition.

    BelgiumGermanyItalyNetherlandsPolandSpainUnited Kingdom
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Study of secukinumab treatment for Giant Cell Arteritis

    This study is testing a drug called Secukinumab to see if it is safe and effective in people with a disease known as giant cell arteritis (GCA). GCA affects blood vessels in the body, causing inflammation. In this study, patients will receive Secukinumab or placebo (a treatment without active medicine) along with a medicine called glucocorticoids, the dose of which will be gradually reduced. The test will test whether a 26-week treatment course is more effective than the current 52-week treatment course. The research team will monitor whether the inflammation subsides and does not return throughout the year. The team will also check how long it will take until the disease symptoms return, how many glucocorticosteroids the patient will need within a year and how his quality of life has improved.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNorwayPolandPortugalSpainSwedenUnited Kingdom
  • Targeting Ovarian Cancer: avutometinib & defactinib study

    This trial tests a drug called avutometinib (VS-6766) alone and together with defactinib. It’s for women with recurrent Low-Grade Serous Ovarian Cancer. This study will examine the safety of these drugs and how effectively they can fight against cancer. Patients will be put into two groups for the study – one will receive only avutometinib (VS-6766) and the other avutometinib (VS-6766) and defactinib combined. The doctors will repeatedly measure the cancer size to check if it has become smaller or stopped growing after taking these drugs.

    BelgiumFranceItalySpainUnited Kingdom
  • Research of combination therapy for metastatic melanoma

    This study looks into a new test treatment for serious skin cancer. It’s a big study, happening in multiple places. It will look at two things: one, a drug called HBI-8000 (Tudicdinostat) taken together with another drug called Nivolumab, and two, just Nivolumab on its own. The main goal is to see which approach works better for patients. Patients who can take part are ones who haven’t tried specific cancer treatments before (PD-1 or PD-L1 inhibitors). However, young people or people with quickly worsening brain tumors can’t take part. The patients are picked based on whether a certain substance is present in their cancer cells (PD-L1 expression) and the LDH level that’s found in their blood.

    AustriaBelgiumCzechiaFranceGermanyItalySpainUnited Kingdom
  • Examining the safety and effectiveness of fazirsiran in people with liver disease due to certain protein abnormality

    This study is looking into a medication called fazirsiran. It is being tested to see if it can help people who have liver disease due to a faulty version of a protein called Alpha-1 Antitrypsin. The researchers want to see if fazirsiran can reduce scarring in the liver and slow down the disease. They will also study how fazirsiran interacts with the body and if it can lower levels of liver inflammation and of the faulty protein. Participants in this study will either get fazirsiran or a placebo (a treatment with no active ingredients). Two liver biopsies will be performed to remove small amounts of liver tissue for examination. Researchers will check for changes in scarring, inflammation, proteins in the liver, and liver stiffness.

    AustriaBelgiumFranceGermanyItalyPolandPortugalSpainUnited Kingdom
  • Comparison of the effectiveness of fingolimod and interferon in multiple sclerosis in children

    This study is about testing a medication called Fingolimod on young patients with Multiple Sclerosis (MS), a condition that affects the nervous system. The main purpose of this study is to check if this medication is safe and effective for these patients. The study will compare Fingolimod with another treatment, Interferon Beta-1a. The entire study will take about 7 years. In the first 2 years, patients will be randomly given either Fingolimod or Interferon Beta-1a without knowing which one they are receiving. In the next 5 years (Extension Phase), all the patients will take Fingolimod. The patients will include children and teenagers. There’s also a smaller group — the younger cohort — these are the kids who are 12 or younger, weigh less than 40 kg, or are not yet in puberty.

    FranceRomaniaSpainUnited Kingdom
  • Study new combination therapy in advanced lung cancer

    This study is about testing a new drug mix to help people with advanced lung cancer (NSCLC) that doesn’t have special gene changes. The research aims to determine whether a combination of three drugs, namely Datopotamab Deruxtecan (Dato-DXd), Durvalumab, and Carboplatin, demonstrates superior efficacy compared to an alternative drug mixture. The people in this study have stage IIIB, IIIC, or IV lung cancer. They will be split in two groups. One group will get Datopotamab Deruxtecan, Durvalumab, and Carboplatin. The other group gets Pembrolizumab and some specific chemo drugs. he primary objective is to assess whether the new three-drug combination can effectively delay cancer growth and extend overall survival time.

    AustriaBulgariaFranceGermanyGreeceHungaryItalyPolandSpainSwedenUnited Kingdom
  • Testing new drug for lung fibrosis safety & effectiveness

    This study explores new treatment options for idiopathic pulmonary fibrosis (IPF) with a new drug called BMS-986278. The main goal is to thoroughly evaluate the effectiveness and safety of BMS-986278 in the treatment of IPF. During the study, participants will receive the drug under close supervision, allowing researchers to collect valuable data on its effects and potential benefits. This careful monitoring also ensures the safety and well-being of each participant. Participating in this study may provide insightful data on how IPF symptoms respond to this new treatment.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainUnited Kingdom

See more clinical trials in other cities in United Kingdom: